Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company’s novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). The presentations will take place at the NASH-TAG Conference, which is being held January 6-8, 2022, in Park City, Utah. Details for the oral presentation are as follows:

Title:	A placebo-controlled, double-blind, first-in-human study of Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist for the treatment of NASH and obesity
Presenter:	Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.
Date/Time:	Saturday, January 8, 2022 at 8:10 am Mountain Time

A copy of Dr. Harris’ presentation and poster will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Investor & Media Contacts:

Richard EisenstadtChief Financial OfficerPhone: [e-mail]